Rheumatism News and Research RSS Feed - Rheumatism News and Research

Rheumatism is a group of disorders marked by inflammation or pain in the connective tissue structures of the body. These structures include bone, cartilage, and fat.
New way to antagonize human nuclear receptor

New way to antagonize human nuclear receptor

On Monday 7 December the journal Nature Communications published the research findings of Eindhoven University of Technology (TU/e), Merck Research Laboratories (Merck is known as MSD outside the US and Canada) and Leiden University concerning an entirely new way of antagonizing a human nuclear receptor. [More]
Researchers identify molecular switch that can avoid inflammation

Researchers identify molecular switch that can avoid inflammation

Our immune system is vital to us and can sometimes overreact causing chronic illnesses, such as for instance rheumatism and allergy. Now, researchers from Umeå University and University of Gothenburg have identified a molecular switch - MYSM1 - that can suppress such an overreaction and avoid inflammation. [More]
Experts and researchers develop new classification criteria for gout

Experts and researchers develop new classification criteria for gout

A panel of experts and researchers have developed a new classification system for gout, the most common form of inflammatory arthritis. This new system standardizes the classification of this condition using a variety of evidence-based criteria. [More]
ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

The American College of Rheumatology (ACR) has released two new publications - recommendations aimed at improving the treatment of patients with polymyalgia rheumatica (PMR), and new classification criteria for gout. [More]
Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Anticentromere and isolated nucleolar autoantibodies are prevalent in systemic sclerosis patients with pulmonary arterial hypertension, but they do not predict survival, US research shows. [More]
Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline. [More]
ImmunArray to launch SLE-key Rule Out test for lupus in select U.S. markets

ImmunArray to launch SLE-key Rule Out test for lupus in select U.S. markets

At the premier European forum on rheumatologic disorders, ImmunArray, maker of a breakthrough technology that provides unprecedented levels of accuracy in ruling out the presence of lupus through a simple blood test, announced today that it is launching its new SLE-key™ Rule Out test in selected U.S. markets on July 1, 2015. [More]
Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third. [More]
People with rheumatoid arthritis less likely to benefit from hepatitis B vaccine

People with rheumatoid arthritis less likely to benefit from hepatitis B vaccine

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that people with rheumatoid arthritis (RA) are less likely to be protected by hepatitis B vaccination than the general population. [More]
Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis (OA). [More]
Study identifies unique bacterial signature in people with systemic sclerosis

Study identifies unique bacterial signature in people with systemic sclerosis

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that people with systemic sclerosis (SSc) have a unique bacterial signature in their colon, when compared with healthy people. [More]
NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) show that diclofenac, naproxen and etoricoxib significantly inhibit ovulation in women with mild musculoskeletal pain. Of the women receiving NSAIDs, only 6.3 percent (diclofenac), 25 percent (naproxen) and 27.3 percent (etoricoxib) ovulated, compared with 100 percent of the control group. [More]
Study shows that ankylosing spondylitis can be predicted by low birth weight

Study shows that ankylosing spondylitis can be predicted by low birth weight

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that a diagnosis of ankylosing spondylitis (AS) can be predicted by low birth weight, having older siblings and hospitalisation for infection between the ages of 5-16 years. [More]
Initial therapy with DMARDs improves disease activity, functional ability in patients with early RA

Initial therapy with DMARDs improves disease activity, functional ability in patients with early RA

The results of the tREACH trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that initial therapy with combination DMARDs significantly improves measures of disease activity and functional ability in patients with early rheumatoid arthritis (RA). [More]
Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. [More]
New results from first real-world study show comparable effectiveness and safety of Hospira’s InflectraTM (infliximab) in patients with rheumatic diseases switched from reference infliximab

New results from first real-world study show comparable effectiveness and safety of Hospira’s InflectraTM (infliximab) in patients with rheumatic diseases switched from reference infliximab

Inflectra received its authorization from the European Commission (EC) in September 2013 for all the licensed indications of Remicade, which has been authorized in the EU since 1999 and recorded European sales of almost €2 billion in 2013... [More]
Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

The comparable safety and efficacy of switching patients to a biosimilar anti-TNF-α monoclonal antibody from the reference medicinal product (RMP) has been further established in data presented at EULAR 2015, the annual meeting of the European League Against Rheumatism. [More]
Raising lupus awareness: an interview with Professor Ramsey-Goldman, MD

Raising lupus awareness: an interview with Professor Ramsey-Goldman, MD

Lupus is a chronic, autoimmune disease, with many different symptoms so it is hard to diagnose. It affects each person differently and it has an unpredictable disease course with flare ups and quiet time. Some patients describe lupus as if they are riding a roller coaster with blinders on because they cannot always tell when they will feel well or sick... [More]
Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints. [More]
Chronic fatigue and rheumatoid arthritis: an interview with Ailsa Bosworth, CE, National Rheumatoid Arthritis Society

Chronic fatigue and rheumatoid arthritis: an interview with Ailsa Bosworth, CE, National Rheumatoid Arthritis Society

Chronic fatigue is about much more than merely feeling tired and when it is at its worst, people feel unable to do almost anything, so it can impact absolutely every area of their life. [More]
Advertisement
Advertisement